Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2145-2152

  Miyake, Makito ^a   Fujimoto, Kiyohide ^a   Anai, Satoshi ^a   Ohnishi, Sayuri ^a   Nakai, Yasushi ^a   Inoue, Takeshi ^a   Matsumura, Yoshiaki ^a   Tomioka, Atsushi ^a   Ikeda, Tomohiro ^a   Okajima, Eijiro ^a   Tanaka, Nobumichi ^a   Hirao, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Drug resistance; Gemcitabine; Heme oxygenase 1; Radiotherapy; Urothelial cancer

Indexed keywords

ACTIN; CASPASE 3; GEMCITABINE; HEME OXYGENASE 1; HISTONE H2AX; PROTOPORPHYRIN ZINC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; URINARY TRACT CANCER;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CYTOPROTECTION; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; HEME OXYGENASE-1; HUMANS; MICE; MICE, INBRED BALB C; PROTOPORPHYRINS; RADIATION TOLERANCE; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955070858     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sugano K and Kakizoe T: Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Nat Clin Pract Urol 3: 642-652, 2006.
2. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608, 2005.
3. Ramalingam S and Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13(SuppI 1): 5-13, 2008.
4. Hezel AF and Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 13: 415-423, 2008.
5. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F and Azria D: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27: 2269-2277, 2009.
6. Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Künzli B, Autschbach F, Meuer S, Büchler MW and Friess H: Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 11: 3790-3798, 2005.
7. Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, Giese NA, Friess H and Kleeff J: Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 99: 760-767, 2008.
8. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W and Sandvold ML: Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 44: 782-786, 2009.
9. Hong SP, Wen J, Bang S, Park S and Song SY: CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125: 2323-2331, 2009.
10. Prawan A, Kundu JK and Surh YJ: Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. Antioxid Redox Signal 7: 1688-1703, 2005.
11. Jozkowicz A, Was H and Dulak J: Heme oxygenase-1 in tumors: Is it a false friend? Antioxid Redox Signal 9: 2099-2117, 2007.
12. Goodman AI, Choudhury M, da Silva JL, Schwartzman ML and Abraham NG: Overexpression of the heme oxygenase gene in renal cell carcinoma. Proc Soc Exp Biol Med 214: 54-61, 1997. (Pubitemid 27051921)
13. Sacca P, Meiss R, Casas G, Mazza O, Calvo JC, Navone N and Vazquez E: Nuclear translocation of haeme oxygenase-1 is associated to prostate cancer. Br J Cancer 97: 1683-1689, 2007.
14. Fang J, Sawa T, Akaike T, Akuta T, Sahoo SK, Khaled G, Hamada A and Maeda H: In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 63: 3567-3574, 2003.
15. Fang J, Sawa T, Akaike T, Greish K and Maeda H: Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 109: 1-8, 2004.
16. Nowis D, Bugajski M, Winiarska M, Bil J, Szokalska A, Salwa P, Issat T, Was H, Jozkowicz A, Dulak J, Stoklosa T and Golab J: Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. BMC Cancer 8: 197, 2008.
17. Miyake M, Ishii M, Kawashima K, Kodama T, Sugano K, Fujimoto K and Hirao Y: siRNA-mediated knockdown of the heme synthesis and degradation pathways: modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines. Photochem Photobiol 85: 1020-1027, 2009.
18. Harris JC, Gilliam AD, McKenzie AJ, Evans SA, Grabowska AM, Clarke PA, McWilliams DF and Watson SA: The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas. Cancer Res 64: 5624-5631, 2004.
19. Anai S, Goodison S, Shiverick K, Iczkowski K, Tanaka M and Rosser CJ: Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther 17: 975-984, 2006.
20. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM and Braakhuis BJ: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22(4 Suppl 11): 72-79, 1995.
21. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530, 1996.
22. von der Maase H, Andersen L, Crinò L, Weinknecht S and Dogliotti L: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10: 1461-1465, 1999.
23. Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W and Seymour L: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 2876-2881, 1999.
24. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W and Stadler W: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921-1927, 2000.
25. Dy SM, Asch SM, Naeim A, Sanati H, Walling A and Lorenz KA: Evidence-based standards for cancer pain management. J Clin Oncol 26: 3879-3885, 2008.
26. Yi SK, Yoder M, Zaner K and Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician 10: 285-290, 2007. (Pubitemid 46553995)
27. Sumiyoshi Y: Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: current status and perspectives. Int J Clin Oncol 9: 484-490, 2004.
28. Lee W, Lockhart AC, Kim RB and Rothenberg ML: Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10: 104-111, 2005.
29. Kleeff J, Michalski C, Friess H and Büchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas 33: 111-118, 2006.
30. Huang P and Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol 22(4 Suppl 11): 19-25, 1995.